TY - JOUR
T1 - Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis
AU - Rocca, Bianca
AU - Fox, Keith A. A
AU - Ajjan, Ramzi A
AU - Andreotti, Felicita
AU - Baigent, Colin
AU - Collet, Jean-Philippe
AU - Grove, Erik L
AU - Halvorsen, Sigrun
AU - Huber, Kurt
AU - Morais, João
AU - Patrono, Carlo
AU - Rubboli, Andrea
AU - Seljeflot, Ingebjorg
AU - Sibbing, Dirk
AU - Siegbahn, Agneta
AU - Ten Berg, Jurrien
AU - Vilahur, Gemma
AU - Verheugt, Freek W. A
AU - Wallentin, Lars
AU - Weiss, Thomas W
AU - Wojta, Johann
AU - Storey, Robert F
PY - 2018
Y1 - 2018
N2 - The success of trials that have shown net clinical benefits of antithrombotic drugs as well as the increasing prevalence of cardiovascular diseases in an ageing population have led to more widespread use of antiplatelet and anticoagulant drugs. At the same time, extremely low and high body weight (BW) are becoming more common due to a higher prevalence of frailty, associated with greater life expectancy, and the global epidemic of obesity, ‘globesity’, respectively.1–3 These extreme BWs may affect cardiovascular risk as well as the pharmacokinetics of antithrombotic drugs, some of which have relatively narrow therapeutic windows.
The ESC Working Group on Thrombosis consequently assembled a task group to examine the key issues related to this topic and to address the question of whether modified antithrombotic management strategies are required for patients at the extremes of BW. Greater focus is given to obesity due to its higher prevalence among patients with cardiovascular disease and the associated complexities in terms of pharmacology and pathophysiology.
AB - The success of trials that have shown net clinical benefits of antithrombotic drugs as well as the increasing prevalence of cardiovascular diseases in an ageing population have led to more widespread use of antiplatelet and anticoagulant drugs. At the same time, extremely low and high body weight (BW) are becoming more common due to a higher prevalence of frailty, associated with greater life expectancy, and the global epidemic of obesity, ‘globesity’, respectively.1–3 These extreme BWs may affect cardiovascular risk as well as the pharmacokinetics of antithrombotic drugs, some of which have relatively narrow therapeutic windows.
The ESC Working Group on Thrombosis consequently assembled a task group to examine the key issues related to this topic and to address the question of whether modified antithrombotic management strategies are required for patients at the extremes of BW. Greater focus is given to obesity due to its higher prevalence among patients with cardiovascular disease and the associated complexities in terms of pharmacology and pathophysiology.
KW - platelets, antithrombotics, atherothrombosis, obesity, body mass
KW - platelets, antithrombotics, atherothrombosis, obesity, body mass
UR - http://hdl.handle.net/10807/116975
U2 - 10.1093/eurheartj/ehy066
DO - 10.1093/eurheartj/ehy066
M3 - Article
SN - 0195-668X
VL - 2018
SP - 1672
EP - 1686
JO - European Heart Journal
JF - European Heart Journal
ER -
